Thermo Fisher Scientific Anthrax Lethal Factor Synthetic Peptide

Applications

Control (Ctrl)

• Assay-dependent

Blocking Assay (BLOCK)

• Assay-dependent

Product Specifications

Product Specific Information

This peptide corresponds to 16 amino acids in the middle of Anthrax lethal factor.

Target Information

Anthrax infection is initiated by the inhalation, ingestion, or cutaneous contact with Bacillus anthracis endospores. B. anthracis produces three polypeptides that comprise the anthrax toxin: protective antigen (PA), lethal factor (LF), and edema factor (EF).

PA binds to two related proteins on the cell surface, termed tumor epithelial marker 8 (TEM8)/anthrax toxin receptor (ATR) and capillary morphogenesis protein 2 (CMG2), though the physiologically relevant receptor remains unclear. After PA binding, it is cleaved by a furin-like protease into two fragments. The bound fragment associates with LF and EF, and the resulting complex is endocytosed, allowing LF and EF translocation into the cytoplasm.

LF is the primary toxin of anthrax and functions as a highly specific protease that cleaves members of the mitogen-activated protein kinase kinase (MAPKK) family near their amino terminus, disrupting MAPK signaling and inducing apoptosis.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.